André Larente from DIAGNOS on Transforming Optometry and Expanding AI Capabilities

April 29, 2024 — In a recent interview with InvestorNews host Tracy Weslosky, André Larente, President, CEO, and Director of DIAGNOS Inc. (TSXV: ADK | OTCQB: DGNOF), discussed the evolving role of optometrists in the face of advancing technology, particularly artificial intelligence (AI) in medical imaging. Larente highlighted how AI is transforming optometry from traditional roles, such as prescribing eyewear, to more complex tasks including monitoring diseases like diabetes and hypertension. He emphasized the imminent obsolescence of refraction equipment, predicting that “the role of the optometrist will change” to focus more on eye health and disease monitoring. This shift, according to Larente, positions optometrists closer to the medical field and specialists, enhancing their role in healthcare.

Larente also shared insights on DIAGNOS’ pioneering efforts in AI for eye health, noting the company’s seven-year history of data collection across 14 countries involving roughly 400,000 patients. This extensive data has facilitated the development of predictive models for diseases affecting the retina. He elaborated on DIAGNOS’ strategic plans, including obtaining Health Canada and US FDA approvals for four new AI analysis modules aimed at expanding the company’s diagnostic capabilities beyond diabetic retinopathy. Larente stated, “These four tests… will actually multiply our revenue potential 4x’s….” underlining the strategic importance of these developments for DIAGNOS’ growth. The company’s commitment to compliance with new regulatory requirements for AI and ongoing partnerships, such as with EssilorLuxottica, further underscore its proactive approach in a competitive field.

To access the complete interview, click here

Don’t miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by clicking here

About DIAGNOS Inc.

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

To learn more about DIAGNOS Inc., click here

Disclaimer: DIAGNOS Inc. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. (“InvestorNews”), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.